Literature DB >> 29444631

Accumulation of Laforin and Other Related Proteins in Canine Lafora Disease With EPM2B Repeat Expansion.

James K Chambers1, Atigan Thongtharb1, Takanori Shiga1, Daigo Azakami2, Miyoko Saito3, Masumi Sato4, Motoji Morozumi5, Hiroyuki Nakayama1, Kazuyuki Uchida1.   

Abstract

Canine Lafora disease (LD) is an autosomal recessive genetic disorder causing nonfatal structural epilepsy, mainly affecting miniature wirehaired dachshunds. Repeat expansion in the EPM2B gene causes a functional impairment of the ubiquitin ligase malin which regulates glycogen metabolism. Abnormally structured glycogen accumulates and develop polyglucosan bodies predominantly in the central nervous system. The authors performed a comprehensive clinical, genetic, and pathological study of 4 LD cases affecting miniature wirehaired dachshund dogs with EPM2B repeat expansions, with systemic distribution of polyglucosan bodies and accumulation of laforin and other functionally associated proteins in the polyglucosan bodies. Myoclonic seizures first appeared at 7-9 years of age, and the dogs died at 14-16 years of age. Immunohistochemistry for calbindin revealed that the polyglucosan bodies were located in the cell bodies and dendritic processes of Purkinje cells. Polyglucosan bodies were also positive for laforin, hsp70, α/β-synuclein, ubiquitin, LC3, and p62. Laforin-positive polyglucosan bodies were located in neurofilament-positive neurons but not in GFAP-positive astrocytes. In nonneural tissues, periodic acid-Schiff (PAS)-positive polyglucosan bodies were observed in the heart, skeletal muscle, liver, apocrine sweat gland, and smooth muscle layer of the urinary bladder. In the skeletal muscle, polyglucosan bodies were observed only in type 1 fibers and not in type 2 fibers. The results indicate that although the repeat expansion of the EPM2B gene is specific to dogs, the immunohistochemical properties of polyglucosan body in canine LD are comparable to human LD. However, important phenotypic variations exist between the 2 species including the affected skeletal muscle fiber type.

Entities:  

Keywords:  EPM2B; Lafora disease; animal model of human disease; autophagy; brain; dog; laforin; muscle fiber type; neuropathology; ubiquitin

Mesh:

Substances:

Year:  2018        PMID: 29444631     DOI: 10.1177/0300985818758471

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  4 in total

1.  Lafora Disease and Alpha-Synucleinopathy in Two Adult Free-Ranging Moose (Alces alces) Presenting with Signs of Blindness and Circling.

Authors:  Madhu Ravi; Atilano Lacson; Margo Pybus; Mark C Ball
Journal:  Animals (Basel)       Date:  2022-06-25       Impact factor: 3.231

Review 2.  Lafora Disease: A Review of Molecular Mechanisms and Pathology.

Authors:  Brandy Verhalen; Susan Arnold; Berge A Minassian
Journal:  Neuropediatrics       Date:  2018-10-18       Impact factor: 1.947

3.  Brain proton magnetic resonance spectroscopy findings in a Beagle dog with genetically confirmed Lafora disease.

Authors:  Neringa Alisauskaite; Katrin Beckmann; Matthias Dennler; Niklaus Zölch
Journal:  J Vet Intern Med       Date:  2020-05-17       Impact factor: 3.333

4.  Suppression of glycogen synthesis as a treatment for Lafora disease: Establishing the window of opportunity.

Authors:  Olga Varea; Jordi Duran; Mònica Aguilera; Neus Prats; Joan J Guinovart
Journal:  Neurobiol Dis       Date:  2020-11-07       Impact factor: 5.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.